Roche
Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection
February 1, 2017Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab
Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …
Juno Therapeutics bring in new executive vice president
January 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, Roche, juno therapeutics
Juno Therapeutics has hired Corsee D. Sanders as its executive vice president and head of development operations. She will step …
MHRA accepts Roche’s Tecentriq into Early Access to Medicines scheme
January 25, 2017Research and Development, Sales and Marketing MHRA, Roche, eams, tecentriq
Roche’s Tecentriq (atezolizumab) has scored another positive opinion, this time from the Medicines and Healthcare products Regulatory Agency (MHRA), which …
Roche’s Actemra granted Priority Review by FDA
January 24, 2017Manufacturing and Production, Sales and Marketing Actemra, FDA, Roche, priority review
Roche’s drug, Actemra (also known as RoActemra in Europe), has been granted priority review designation by the FDA for the …
22 pharma companies join forces for global non-communicable disease initiative
January 18, 2017Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda
The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …
MSD looks to jump the gun with combination immunotherapy application
January 11, 2017Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda
MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …
Roche’s Tecentriq scores another bladder cancer Priority Review
January 9, 2017Sales and Marketing Roche, bladder cancer, tecentriq
Roche has announced that its immunotherapy drug Tecenetriq (atezolizumab) has been awarded Priority Review by the FDA for the treatment …
Insider interview: Roche discusses the importance of sustainability in pharma manufacturing
January 6, 2017Manufacturing and Production, Medical Communications Roche
Peter Schurrenberger, Chief Safety, Health and Environment Officer at Roche, discusses their recent recognition as a leader for corporate action …
Roche’s ground-breaking MS drug delayed by manufacturing issues
December 22, 2016Genentech, MS, Roche, multiple sclerosis
Roche has released both good and bad news just before Christmas. The good news is very good news for individuals …
Genentech announces Bill Anderson as new CEO
December 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bill Anderson, Genentech, Roche
Genentech, the biotech subsidiary of Roche, has announced that Genentech veteran, Ian Clark, will retire as CEO on 1 January. …
Neurodegenerative market to be worth $45 billion by 2022
December 12, 2016Sales and Marketing Biogen, GBI Research, Novartis, Roche, Sanofi, neurodegenerative
Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which …
First generic copy of Roche’s Tamiflu hits US market
December 12, 2016Sales and Marketing Alvogen, Roche, Tamiflu
Drugmaker Alvogen has released the first generic version of Roche’s flu medication Tamiflu (oseltamivir) in the US, where it expects …
Merck and Roche extend distribution ties
December 5, 2016Manufacturing and Production Merck, Roche, distribution
Merck KGaA and Roche have announced that they will further increase the distribution links between the two companies by having …
Patheon acquires state-of-the-art manufacturing facility from Roche
November 28, 2016Manufacturing and Production Patheon, Roche, South Carolina
Patheon, a provider of drug development and delivery to the pharmaceutical and biopharma sectors, announced that it has acquired a …
Insider interview: Roche discusses efficacy of CDF and NICE
November 25, 2016Medical Communications, Sales and Marketing CDF, NICE, Roche
Deborah Lancaster, Head of Market Access at Roche, discusses, in the latest issue of Pharmafile, the efficacy of the National …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
